Nextcure ((NXTC)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NextCure, Inc. has announced an update on its ongoing clinical study titled ‘A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, and optimal dosing of LNCB74, a promising treatment for various advanced solid tumors, including ovarian, breast, and lung cancers. This study is significant as it explores a novel therapeutic approach that could potentially improve outcomes for patients with limited treatment options.
The intervention being tested is LNCB74, an antibody drug conjugate designed to target B7-H4, a protein often overexpressed in certain tumors. The drug is administered intravenously in 21-day cycles, with the goal of determining the maximum tolerated dose and the recommended phase 2 dose.
The study follows an interventional design with a randomized allocation and a sequential intervention model. It is an open-label trial, meaning there is no masking, and its primary purpose is treatment-focused. The study is structured in two parts: dose escalation and dose expansion, to thoroughly evaluate the drug’s safety and efficacy.
The study commenced on January 8, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on May 13, 2025, indicating ongoing recruitment and progress in the trial.
This update could positively influence NextCure’s stock performance, as successful outcomes may lead to increased investor confidence and potential market expansion. The involvement of LigaChem Biosciences, Inc. as a collaborator also highlights industry interest in this innovative treatment. Investors should monitor this study closely, as advancements could impact the competitive landscape in oncology therapeutics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.